Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Merck KGaA prefers alliances to mergers; signs new deal with ImClone Systems

Dec. 16, 1998

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Dec. 16, 1998

Clinical studies support excellent safety and efficacy of Busulfex

Dec. 15, 1998

New antitumor compounds presented by Kyorin

Dec. 15, 1998

Oxigene describes mechanism of action, therapeutic potential of declopramide

Dec. 15, 1998

Celgene acquires EntreMed rights to thalidomide

Dec. 14, 1998

AEterna signs CTA with NCI and reports lung cancer pivotal trial protocol details

Dec. 14, 1998

Dendritic cell therapies based on Dendreon technology focus of Dendreon-Kirin partnership

Dec. 14, 1998

Decitabine considered a promising treatment option for high-risk patients with MDS

Dec. 11, 1998

Mouse studies indicate that IL-12 gene therapy is a feasible and effective treatment for AML

Dec. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...